Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MWPC-003 is an investigational **sterile injectable bromelain solution** composed of a mixture of medical-grade proteolytic enzymes and developed by MediWound for **Dupuytren contracture**. It is a biologic enzyme therapy administered by local injection, with pharmacology described as anti-inflammatory, immunomodulatory, and protein-modulating. Its intended therapeutic effect appears to derive from the **proteolytic activity of bromelain enzymes**, which can enzymatically modulate or degrade pathologic protein-rich connective tissue within the fibrotic lesion in Dupuytren contracture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MWPC-003.